Management of Left Atrial Enlargement and Mild Pulmonary Hypertension

Primary Management Strategy

The American College of Cardiology recommends aggressive treatment of the underlying left heart disease with guideline-directed medical therapy, as left atrial enlargement with mild pulmonary hypertension represents Group 2 pulmonary hypertension (PH-LHD) where the elevated pulmonary pressures result from passive backward transmission of elevated left-sided filling pressures 1, 2

Comprehensive Doppler echocardiography should be performed to assess left ventricular systolic and diastolic function, valvular morphology and function, left atrial size, and estimate pulmonary artery pressures, according to the American Heart Association 3, 4
Left atrial enlargement, even without definite left ventricular dysfunction, indicates elevated left-sided filling pressures contributing to pulmonary pressure elevation, as stated by the American College of Chest Physicians 3
Right heart catheterization should be considered if pulmonary hypertension appears severe or disproportionate to left heart disease, measuring pulmonary capillary wedge pressure (PCWP >15 mmHg confirms PH-LHD), as recommended by the European Respiratory Society 5, 2

The American College of Cardiology recommends administering diuretics aggressively to reduce left-sided filling pressures and pulmonary congestion 1, 2
ACE inhibitors or ARBs should be prescribed for afterload reduction and to prevent/reverse left ventricular hypertrophy, particularly in hypertensive patients, according to the American Heart Association 1, 2
Target strict blood pressure control, as hypertension is a primary driver of left atrial enlargement and diastolic dysfunction, as stated by the American College of Cardiology 2
Beta-blockers should be initiated when indicated for underlying heart failure or to optimize diastolic filling time, as recommended by the American Heart Association 1, 2
SGLT2 inhibitors should be added for heart failure with preserved ejection fraction (HFpEF), as they improve pulmonary pressures, according to the American College of Cardiology 1
Sacubitril/valsartan (ARNI) should be considered for appropriate heart failure phenotypes, as recommended by the American Heart Association 1
Mineralocorticoid receptor antagonists should be added as part of guideline-directed therapy, according to the American College of Cardiology 1

Mitral valve surgery is indicated for symptomatic patients with severe primary mitral regurgitation and LVEF >30%, with mitral valve repair preferred over replacement, as recommended by the American College of Cardiology 4, 7
Mitral valve surgery is indicated for asymptomatic patients with severe primary mitral regurgitation and left ventricular dysfunction (LVEF 30-60% or LVESD ≥40 mm), according to the American Heart Association 4, 7

The European Society of Cardiology recommends against using PAH-specific therapies (endothelin receptor antagonists, prostacyclin analogs, phosphodiesterase-5 inhibitors, or riociguat) in PH-LHD, as this is a Class III recommendation (harm) 5, 1, 2
Randomized trials of epoprostenol and bosentan in heart failure were terminated early due to increased adverse events, as reported by the American College of Cardiology 2
Riociguat showed no benefit on mean pulmonary artery pressure in a 201-patient trial of PH due to systolic heart failure, according to the European Respiratory Society 5

Misdiagnosing PH-LHD as pulmonary arterial hypertension (PAH) and initiating PAH-specific therapy is a critical error that causes patient harm, as stated by the American College of Cardiology 1
Failing to optimize volume status before invasive hemodynamic assessment can lead to inaccurate diagnosis, according to the European Respiratory Society 5
Overlooking diastolic dysfunction as the primary cause when left ventricular systolic function appears normal—up to 60-70% of patients with isolated diastolic dysfunction develop pulmonary hypertension, as reported by the American College of Cardiology 2
Not performing contrast echocardiography to exclude intracardiac shunting when the diagnosis is uncertain, as recommended by the American College of Chest Physicians 3